Related Experiment Video
Updated: Jun 16, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Changes in glitazone use among office-based physicians in the U.S., 2003-2009
Andrew Cohen1, Atonu Rabbani, Nilay Shah
1Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA.
Diabetes Care
|January 28, 2010
Summary
Glitazone use has shifted, with rosiglitazone declining significantly after FDA advisories. Pioglitazone use, however, remained stable, unaffected by the class-level advisory.
Area of Science:
- Pharmacology and Therapeutics
- Drug Utilization Research
- Public Health Interventions
Background:
- Glitazone medications (thiazolidinediones) are used to treat type 2 diabetes.
- Recent trends in glitazone prescribing patterns are not well-documented.
- Understanding drug utilization is crucial for public health and clinical practice.
Purpose of the Study:
- To analyze recent changes in the utilization of glitazone medications.
- To investigate the impact of regulatory actions and scientific information on glitazone prescribing.
Main Methods:
- Utilized interrupted time series analyses.
- Employed nationally representative office-visit data from IMS Health's National Disease and Therapeutic Index.
- Examined glitazone use trends from 2003 to 2007/2008.
Main Results:
- Glitazone use initially increased (2003-2005).
- Rosiglitazone use declined by 16% annually (2005-2007) and sharply after FDA advisories (Feb 2007-May 2008).
- Pioglitazone use increased 14% annually (2005-2007) and remained stable, comprising 77% of glitazone use by 2008.
Conclusions:
- Scientific publications, advisories, and media significantly reduced rosiglitazone use.
- Pioglitazone use was not similarly impacted by class-level FDA advisories.
- Differential responses to safety information highlight varied perceptions and impacts of regulatory actions on specific drugs.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...